Acute Respiratory Distress Syndrome (Ards) Market is expected to portray promising scenarios, as it is estimated to reach $934.8 million in 2030 which was initially valued at around $583.9 million in 2021, thereby registering a CAGR of nearly 6% from 2022 to 2030.
During the COVID-19 epidemic, the life sciences industry has played a critical role. To deal with the worldwide issue, traditional...